ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Dermatology · Acta Derm Venereol · 2026-11-17

Meta-analysis of 14 observational studies (464 biologic treatment lines) in pityriasis rubra pilaris: pooled complete/near-complete response 0.36, any response 0.73. No significant difference between TNF, IL-17 and IL-23 pathway inhibitor classes (p=0.057); AEs in 12/183 courses.

Meta-analysisn = 464 biologic therapeutic lines
Tartaglia et al. Biologic Therapy in Pityriasis Rubra Pilaris: Systematic Review and Meta-analysis with Class-based Comparisons
Rheumatology · RMD Open · 2026-06-24

Network meta-analysis of 99 RCTs in rheumatoid arthritis: JAK inhibitors (HAQ MD −0.13) and IL-6 inhibitors (MD −0.13) reduced activity limitation more than TNF inhibitors; no other significant class differences in pain, fatigue or physical or mental health.

Meta-analysisn = 99 trials
van Esveld et al. Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses
Rheumatology · Ann Rheum Dis · 2025-12-25

Meta-analysis of 31 placebo-controlled RCTs (n=6437) of TNF and IL-17 inhibitors in axial spondyloarthritis: treatment effect on ASAS20 declined 5% per year, driven by rising placebo response; ASDAS-based treatment effects stayed stable.

Meta-analysisn = 6,437
Perrot et al. Evaluation of the placebo and treatment effect overtime in randomised clinical trials evaluating the efficacy of biologics in axial spondyloarthritis: systematic review and meta-analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.